Last reviewed 2026-04-22 · How we verify

DHA/piperaquine and a SLD-PQ

DHA/piperaquine is a fixed-dose artemisinin-based combination therapy that kills malaria parasites through multiple mechanisms, while SLD-PQ (second-line drug with piperaquine) provides additional antimalarial activity.

DHA/piperaquine is a fixed-dose artemisinin-based combination therapy that kills malaria parasites through multiple mechanisms, while SLD-PQ (second-line drug with piperaquine) provides additional antimalarial activity. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by other Plasmodium species (P. vivax, P. ovale, P. malariae, P. knowlesi).

At a glance

Mechanism of action

Dihydroartemisinin (DHA) is a fast-acting artemisinin derivative that rapidly reduces parasite biomass by generating reactive oxygen species and damaging parasite proteins and membranes. Piperaquine is a bisquinoline that accumulates in parasitized red blood cells and inhibits heme detoxification, leading to parasite death. The combination provides synergistic activity with rapid parasite clearance and extended post-treatment prophylaxis.

Approved indications

• Uncomplicated malaria caused by Plasmodium falciparum
• Malaria caused by other Plasmodium species (P. vivax, P. ovale, P. malariae, P. knowlesi)

Common side effects

• Headache
• Fever
• Nausea
• Vomiting
• Abdominal pain
• Diarrhea
• Dizziness
• Pruritus

Key clinical trials

• Mass Vaccine and Drug Administration, Bangladesh (PHASE4)
• Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.